Bicara Therapeutics Inc. (BCAX)
| Market Cap | 1.82B +220.0% |
| Revenue (ttm) | n/a |
| Net Income | -157.32M |
| EPS | -2.80 |
| Shares Out | 65.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 949,332 |
| Open | 27.83 |
| Previous Close | 28.06 |
| Day's Range | 27.07 - 28.40 |
| 52-Week Range | 9.57 - 30.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.46 (+13.45%) |
| Earnings Date | Aug 11, 2026 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BCAX stock is "Buy." The 12-month stock price target is $31.46, which is an increase of 13.45% from the latest price.
News
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics Transcript: Study update
Ficera demonstrated robust, durable efficacy in first-line HPV-negative head and neck cancer, doubling three-year overall survival versus standard of care and achieving deep responses in most patients. Safety was manageable, and biomarker data confirmed the mechanism of action, supporting ongoing pivotal trials.
Bicara Therapeutics Press release: Study update
Bicara Therapeutics issued a press release on May 22, 2026, disclosing material business information to investors.
Bicara Therapeutics Slides: Study update
Bicara Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
Bicara Therapeutics management to meet with Cantor
Meeting to be held in New York on May 26 hosted by Cantor.
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrosp...
Bicara Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Ficerafusp alfa shows deep and durable responses in head and neck cancer, especially in HPV-negative patients, with a pivotal phase III readout expected mid-2025. The company is well-funded, targeting a major market opportunity, and plans further data updates at ASCO.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wit...
Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Bicara Therapeutics (BCAX) to $37 from $36 and keeps an Overweight rating on the shares. The first quarter was focused on continued…
Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $18 from $16 and keeps a Neutral rating on the shares. The firm updated its model following the…
Bicara Therapeutics reports Q1 EPS (93c), consensus (65c)
“The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone of treatment in HPV-negative head and neck cancer. In addition to advancing…
Bicara Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and operational progress, with FICERA advancing in pivotal trials and new leadership supporting commercial readiness. Financial position was bolstered by an oversubscribed offering, extending cash runway into 2029.
Bicara Therapeutics Earnings release: Q1 2026
Bicara Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Bicara Therapeutics Slides: Q1 2026
Bicara Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Bicara Therapeutics Quarterly report: Q1 2026
Bicara Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026
Bicara Therapeutics initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target With 12 months to the company’s first Phase 3 data for ficerafusp alfa…
Bicara Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target
Bicara Therapeutics Slides: Corporate presentation
Bicara Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wit...
Bicara Therapeutics Proxy statement: Proxy filing
Bicara Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Bicara Therapeutics Proxy statement: Proxy filing
Bicara Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...